The Cartagena Protocol on Biosafety that was adopted by governments on 29 January 2000 is the main international legally binding treaty that regulates ?the safe transfer, handling and use of living modified organisms resulting from modern biotechnology? that may have adverse effects on the conservation and sustainable use of biological diversity, taking also into account risks to human health?.

It is significant as the first global treaty to attempt to contribute to the protection of biodiversity and human health in this field, and as the first treaty to operationalise the precautionary approach in decision-making relating to imports under the Protocol. As of 22 February 2005, there are 113 Parties to the Protocol.

Although the Protocol focuses on transboundary movements of GMOs, its provisions do influence national and regional biosafety policies and laws, bearing in mind that the Protocol sets minimum requirements and Parties have the right to formulate more comprehensive national laws with higher standards. This is reaffirmed in Article 2(4).

Meanwhile, work and standard setting are also taking place in other international fora, such as the Codex Alimentarius, the International Plant Protection Convention and the International Office of Epizootics, the UN Food and Agriculture Organisation and the World Health Organisation.

The linkages among trade, environment and health means that developments at the World Trade Organisation also impact on biosafety and vice versa.

A field of growing importance is the development of biological weapons as part of biodefence programmes where the adequacy of global rules and standards needs examinination.

Relief as Parties to the Biosafety Protocol adopt key decisions

TWN report on the outcomes of the Sixth Meeting of the Parties to the Cartagena Protocol on Biosafety […]

Socio-Economic Considerations under the Cartagena Protocol on Biosafety – Insights for Effective Implementation

This briefing provides insights for effective implementation of the Cartagena Protocol provision on socio-economic considerations. […]

The AHTEG Guidance on Risk Assessment of LMOs

This briefing on the AHTEG Guidance of Risk Assessment of LMOs explains the strengths of the Guidance, including that for the monitoring of LMOs released into the environment. […]

Some Key Issues for COP-MOP6

An overview of some of the key issues on the agenda for COP-MOP6 and what steps need to be taken to ensure effective implementation of the Cartagena Protocol. […]

Report of COP-MOP5: Biosafety Protocol Steps Forward

TWN report on the outcomes of COP-MOP5, which met in Nagoya, Japan from 11-15 October 2010. […]

Analysis of the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress

This article analyzes the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress to the Cartagena Protocol on Biosafety and highlights the implementation challenges. […]

Developing Countries Propose TRIPS Amendment to Fight Biopiracy

A large group of developing countries has proposed that the WTO’s intellectual property agreement be amended to require the disclosure of origin of genetic resources and/or associated traditional knowledge in patent applications. […]

Nagoya Protocol: Analysis and Implementation Options for Developing Countries

A research paper by the South Centre analysing the Nagoya Protocol on Access and Benefit Sharing of Genetic Resources and its reference to developing countries. […]

“Milestone” Virus/Benefit-Sharing Agreement with Shortcomings

A milestone is reached at the WHO on an agreement governing the sharing of influenza viruses and resulting public health benefits including vaccines and diagnostic kits. […]

The Nagoya Protocol and Pathogens

This is a Policy Brief by the South Centre on the Nagoya Protocol on Access and Benefit Sharing and the issue of microorganisms. […]